725 related articles for article (PubMed ID: 33203663)
1. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
2. Implication of
Gao Y; Luo Q; Sun Z; Gao H; Yu Y; Sun Y; Ma X; Han C; Shi J; Wang F
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36858461
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
[No Abstract] [Full Text] [Related]
4. Noninvasive Imaging of Tumor PD-L1 Expression Using [
Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
[TBL] [Abstract][Full Text] [Related]
6. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
7. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
8. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
[TBL] [Abstract][Full Text] [Related]
10. Inter-rater and intra-rater agreement of [
Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
[TBL] [Abstract][Full Text] [Related]
11. Novel small
Liang Z; Hu X; Hu H; Wang P; Cai J
Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
[TBL] [Abstract][Full Text] [Related]
12. Inter- and intraobserver agreement of the quantitative assessment of [
Hughes DJ; Chand G; Goh V; Cook GJR
EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
14. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
15. Synergy between
Zhu YC; Elsheikha HM; Wang JH; Fang S; He JJ; Zhu XQ; Chen J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725213
[TBL] [Abstract][Full Text] [Related]
16. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development and characterisation of
Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
19.
Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
[TBL] [Abstract][Full Text] [Related]
20. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
